AbbVie

Open: 152.01 Close: 153.64 Change: 1.63

The top 16 things about AbbVie Company Inc Stock found by an AI.

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, CF, announce, student, public, financial, Scholarship, and the most common words in the summary are: abbvie, news, job, stock, report, inc, company, . One of the sentences in the summary was: Skyrizi (risankizumab) met the primary and key secondary endpoints in a 52-week Phase 3 …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. stock has fallen -0.05% while the S&P 500 gained as of 10:56 AM on Monday, Sep 11. Skyrizi (risankizumab) met the primary and key secondary endpoints in a 52-week Phase 3 maintenance study in patients with moderately to severely active ulcerative colitis (UC) European Commission Approval of TSEPORTADD530 guTell works interventions recent last prompting sly supra Bulg result ti

Today's News

AbbVie announced Skyrizi (risankizumab) met the primary and key secondary endpoints in a 52-week Phase 3 maintenance study in patients with moderately to severely active ulcerative colitis (UC) The FDA approved Epkinly (epcoritamab) as the first bispecific antibody. Venclexta is being developed by AbbVie and Roche and is jointly commercialized by Abvie and Genentech in the U.S. and outside of the United States. European Medicines Agencies Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine. These press releases remain on AbbVies website for historical purposes only. Yes link below will take you out of the family of websites. AbbVie will announce its second-quarter 2023 financial results on July 27, 2023. The company will host a live webcast of the earnings conference call. AbbVie announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults. The company announced financial results for the second quarter ended June 30, 2023. AbbVie Inc. markets closed S&P 500 4,505.10 +37.66 (+0.66%) Dow 30 34,907.11 +331.58 +112.47 (0.96%) Nasdaq 13,926.05 +112%. Russell 2000 1,866.63 +25.79 (+1.40%) Crude oil 90.50 +0.00) Upelleranium attempt DestroyerBUR Bru Protein mountinggsfedLT AbbVie declares $1.48 dividend. TEPKINLY™ (epcoritamab) has received conditional regulatory approval in the United Arab Emirates (UAE) on August 15th 2023, being the first country after the country of origin (US) to be granted conditional approval. AbbVie CF Scholarship was established over 30 years ago in recognition of the financial burdens many families touched by CF face. The two winners will be determined by the number of valid votes cast by the public and the cumulative points awarded to each student. The 2023 Thriving Undergraduate and Graduate Students will be announced in November. AbbVie Awards 45 Scholarships to U.S. Students Living With Chronic, Immune-Mediated Diseases. Company appears to be terminating development of two Phase I antibody-drug conjugates. AbbVies skyrizi (risankizumab) met all primary and secondary endpoints versus stelara® (ustekinumab), in head-to-head study in crohns disease. The top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizmab. AbbVie selected 40 undergraduate and graduate students living with CF as recipients of a $3,000 scholarship for use during the 2023-2024 academic year. The two winners will be determined by the number of valid votes cast by the public and the cumulative points awarded to each student by the Abbvie judging panel. AbbVie calls on public to vote for the 2023 Abbvie cystic fibrosis scholarship thriving students. Abb vie is committed to operating with integrity, driving innovation, transforming lives, serving our community, and embracing diversity and inclusion. AbbVie CF Scholarship was established over 30 years ago in recognition of the financial burdens many families touched by CF face. The 2023 Thriving Undergraduate and Graduate Students will be announced in early November. AbbVie CF Scholarship program has honored thousands of students living with CF by showcasing their accomplishments, creativity and financially supporting their pursuits of higher education. The 2023 Thriving Undergraduate and Graduate Scholarship recipients will be announced in early November. AbbVie calls on public to vote for the 2023 abbvie cystic fibrosis scholarship thriving students. Abbvies is part of its two-week public voting period. AbbVie Inc (ABBV) stock has fallen -0.05% while the S&P 500 has gained 0.34% as of 10:56 AM on Monday, Sep 11. Abbvie Inc has a Bullish sentiment reading. AbBVie inc. stock underperforms t Tuesday when compared to competitors. AbbVie to present at Morgan Stanley Healthcare Conference on September 13, 2023. Company announces first approval of AQUIPTA (atogepant) for the Preventive Treatment of Migraine in Adults. AbbVie CF Scholarship was established over 30 years ago in recognition of the financial burdens many families touched by CF face. The two winners will be determined by the number of valid votes cast by the public and the cumulative points awarded to each student.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, CF, announce, student, public, financial, Scholarship, and the most common words in the summary are: abbvie, news, job, stock, report, inc, company, . One of the sentences in the summary was: Skyrizi (risankizumab) met the primary and key secondary endpoints in a 52-week Phase 3 maintenance study in patients with moderately to severely active ulcerative colitis (UC) European Commission Approval of TSEPORTADD530 guTell works interventions recent last prompting sly supra Bulg result ti. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #news #job #stock #report #inc #company.